Literature DB >> 23875777

Synaptodendritic recovery following HIV Tat exposure: neurorestoration by phytoestrogens.

Sarah J Bertrand1, Charles F Mactutus, Marina V Aksenova, Tori D Espensen-Sturges, Rosemarie M Booze.   

Abstract

HIV-1 infects the brain and, despite antiretroviral therapy, many infected individuals suffer from HIV-1-associated neurocognitive disorders (HAND). HAND is associated with dendritic simplification and synaptic loss. Prevention of synaptodendritic damage may ameliorate or forestall neurocognitive decline in latent HIV-1 infections. The HIV-1 transactivating protein (Tat) is produced during viral latency in the brain and may cause synaptodendritic damage. This study examined the integrity of the dendritic network after exposure to HIV-1 Tat by labeling filamentous actin (F-actin)-rich structures (puncta) in primary neuronal cultures. After 24 h of treatment, HIV-1 Tat was associated with the dendritic arbor and produced a significant reduction of F-actin-labeled dendritic puncta as well as loss of dendrites. Pre-treatment with either of two plant-derived phytoestrogen compounds (daidzein and liquiritigenin), significantly reduced synaptodendritic damage following HIV-1 Tat treatment. In addition, 6 days after HIV-1 Tat treatment, treatment with either daidzein, or liquiritigenin enhanced recovery, via the estrogen receptor, from HIV-1 Tat-induced synaptodendritic damage. These results suggest that either liquiritigenin or daidzein may not only attenuate acute synaptodendritic injury in HIV-1 but may also promote recovery from synaptodendritic damage. The HIV-1 transactivating protein (Tat) is produced during viral latency in the brain. Treatment with either daidzein or liquiritigenin restored the loss of synaptic connectivity produced by HIV-1 Tat. This neurorestoration was mediated by estrogen receptors (ER). These results suggest that plant-derived phytoestrogens may promote recovery from HIV-1-induced synaptodendritic damage.
© 2013 International Society for Neurochemistry.

Entities:  

Keywords:  F-actin; HAND; cell culture; daidzein; liquiritigenin; rat

Mesh:

Substances:

Year:  2013        PMID: 23875777      PMCID: PMC4041987          DOI: 10.1111/jnc.12375

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  62 in total

1.  Estrogen receptor ß activity modulates synaptic signaling and structure.

Authors:  Deepak P Srivastava; Kevin M Woolfrey; Feng Liu; Nicholas J Brandon; Peter Penzes
Journal:  J Neurosci       Date:  2010-10-06       Impact factor: 6.167

2.  Subtype selective NMDA receptor antagonists induce recovery of synapses lost following exposure to HIV-1 Tat.

Authors:  A H Shin; H J Kim; S A Thayer
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

3.  A regulatory role for actin in dendritic spine proliferation.

Authors:  Orenda L Johnson; Charles C Ouimet
Journal:  Brain Res       Date:  2006-08-28       Impact factor: 3.252

4.  Rapid effects of estrogen receptor α and β selective agonists on learning and dendritic spines in female mice.

Authors:  Anna Phan; Karla E Lancaster; John N Armstrong; Neil J MacLusky; Elena Choleris
Journal:  Endocrinology       Date:  2011-02-01       Impact factor: 4.736

5.  Cortical synaptic density is reduced in mild to moderate human immunodeficiency virus neurocognitive disorder. HNRC Group. HIV Neurobehavioral Research Center.

Authors:  I P Everall; R K Heaton; T D Marcotte; R J Ellis; J A McCutchan; J H Atkinson; I Grant; M Mallory; E Masliah
Journal:  Brain Pathol       Date:  1999-04       Impact factor: 6.508

6.  Effects of liquiritigenin treatment on the learning and memory deficits induced by amyloid beta-peptide (25-35) in rats.

Authors:  Rui Ting Liu; Li Bo Zou; Jie Ying Fu; Qiu Jun Lu
Journal:  Behav Brain Res       Date:  2010-02-01       Impact factor: 3.332

7.  Interactive comorbidity between opioid drug abuse and HIV-1 Tat: chronic exposure augments spine loss and sublethal dendritic pathology in striatal neurons.

Authors:  Sylvia Fitting; Ruqiang Xu; Cecilia Bull; Shreya K Buch; Nazira El-Hage; Avindra Nath; Pamela E Knapp; Kurt F Hauser
Journal:  Am J Pathol       Date:  2010-07-22       Impact factor: 4.307

8.  Liquiritigenin attenuates the learning and memory deficits in an amyloid protein precursor transgenic mouse model and the underlying mechanisms.

Authors:  Rui Ting Liu; Jin Tian Tang; Li Bo Zou; Jie Ying Fu; Qiu Jun Lu
Journal:  Eur J Pharmacol       Date:  2011-08-22       Impact factor: 4.432

9.  Regulation of dendritic spine density in cultured rat hippocampal neurons by steroid hormones.

Authors:  D D Murphy; M Segal
Journal:  J Neurosci       Date:  1996-07-01       Impact factor: 6.167

10.  Oxidative in vitro metabolism of liquiritigenin, a bioactive compound isolated from the Chinese herbal selective estrogen beta-receptor agonist MF101.

Authors:  René Kupfer; Leah Swanson; Sylvia Chow; Richard E Staub; Yan Ling Zhang; Isaac Cohen; Uwe Christians
Journal:  Drug Metab Dispos       Date:  2008-07-31       Impact factor: 3.922

View more
  32 in total

1.  HIV-1 Tat activates a RhoA signaling pathway to reduce NMDA-evoked calcium responses in hippocampal neurons via an actin-dependent mechanism.

Authors:  Kelly A Krogh; Elizabeth Lyddon; Stanley A Thayer
Journal:  J Neurochem       Date:  2014-09-18       Impact factor: 5.372

2.  Endocannabinoids exert CB1 receptor-mediated neuroprotective effects in models of neuronal damage induced by HIV-1 Tat protein.

Authors:  Changqing Xu; Douglas J Hermes; Blessing Nwanguma; Ian R Jacobs; Kenneth Mackie; Somnath Mukhopadhyay; Aron H Lichtman; Bogna Ignatowska-Jankowska; Sylvia Fitting
Journal:  Mol Cell Neurosci       Date:  2017-07-19       Impact factor: 4.314

3.  Neuroprotective effects of fatty acid amide hydrolase catabolic enzyme inhibition in a HIV-1 Tat model of neuroAIDS.

Authors:  Douglas J Hermes; Changqing Xu; Justin L Poklis; Micah J Niphakis; Benjamin F Cravatt; Ken Mackie; Aron H Lichtman; Bogna M Ignatowska-Jankowska; Sylvia Fitting
Journal:  Neuropharmacology       Date:  2018-08-13       Impact factor: 5.250

4.  Region-specific effects of HIV-1 Tat on intrinsic electrophysiological properties of pyramidal neurons in mouse prefrontal cortex and hippocampus.

Authors:  Thomas J Cirino; Scott W Harden; Jay P McLaughlin; Charles J Frazier
Journal:  J Neurophysiol       Date:  2020-02-26       Impact factor: 2.714

Review 5.  HIV-associated neurodegeneration: exploitation of the neuronal cytoskeleton.

Authors:  Erin D Wenzel; Valeria Avdoshina; Italo Mocchetti
Journal:  J Neurovirol       Date:  2019-03-08       Impact factor: 2.643

6.  Interactive HIV-1 Tat and morphine-induced synaptodendritic injury is triggered through focal disruptions in Na⁺ influx, mitochondrial instability, and Ca²⁺ overload.

Authors:  Sylvia Fitting; Pamela E Knapp; Shiping Zou; William D Marks; M Scott Bowers; Hamid I Akbarali; Kurt F Hauser
Journal:  J Neurosci       Date:  2014-09-17       Impact factor: 6.167

7.  Dose-dependent neurocognitive deficits following postnatal day 10 HIV-1 viral protein exposure: Relationship to hippocampal anatomy parameters.

Authors:  Sylvia Fitting; Kristen A McLaurin; Rosemarie M Booze; Charles F Mactutus
Journal:  Int J Dev Neurosci       Date:  2017-10-27       Impact factor: 2.457

8.  HIV-1 transgenic female rat: synaptodendritic alterations of medium spiny neurons in the nucleus accumbens.

Authors:  Robert F Roscoe; Charles F Mactutus; Rosemarie M Booze
Journal:  J Neuroimmune Pharmacol       Date:  2014-07-19       Impact factor: 4.147

9.  Cannabinoids Occlude the HIV-1 Tat-Induced Decrease in GABAergic Neurotransmission in Prefrontal Cortex Slices.

Authors:  Changqing Xu; Douglas J Hermes; Ken Mackie; Aron H Lichtman; Bogna M Ignatowska-Jankowska; Sylvia Fitting
Journal:  J Neuroimmune Pharmacol       Date:  2016-03-18       Impact factor: 4.147

10.  S-EQUOL: a neuroprotective therapeutic for chronic neurocognitive impairments in pediatric HIV.

Authors:  Kristen A McLaurin; Hailong Li; Anna K Cook; Rosemarie M Booze; Charles F Mactutus
Journal:  J Neurovirol       Date:  2020-09-01       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.